WO2011147280A1 - 一种恩诺沙星注射液及其制备方法 - Google Patents
一种恩诺沙星注射液及其制备方法 Download PDFInfo
- Publication number
- WO2011147280A1 WO2011147280A1 PCT/CN2011/074426 CN2011074426W WO2011147280A1 WO 2011147280 A1 WO2011147280 A1 WO 2011147280A1 CN 2011074426 W CN2011074426 W CN 2011074426W WO 2011147280 A1 WO2011147280 A1 WO 2011147280A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enrofloxacin
- injection
- chelating agent
- solution
- sodium
- Prior art date
Links
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960000740 enrofloxacin Drugs 0.000 title claims abstract description 68
- 238000002347 injection Methods 0.000 title claims abstract description 48
- 239000007924 injection Substances 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 48
- 239000007864 aqueous solution Substances 0.000 claims abstract description 25
- 239000002738 chelating agent Substances 0.000 claims abstract description 20
- 239000002535 acidifier Substances 0.000 claims abstract description 18
- 230000007935 neutral effect Effects 0.000 claims abstract description 17
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims abstract description 9
- 235000019345 sodium thiosulphate Nutrition 0.000 claims abstract description 9
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 8
- 239000004310 lactic acid Substances 0.000 claims abstract description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical group [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims abstract description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims abstract description 7
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims abstract description 5
- 239000004475 Arginine Substances 0.000 claims abstract description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000000243 solution Substances 0.000 claims description 31
- 229940079827 sodium hydrogen sulfite Drugs 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000005374 membrane filtration Methods 0.000 claims 1
- 238000001471 micro-filtration Methods 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 230000000622 irritating effect Effects 0.000 abstract description 3
- 239000012467 final product Substances 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012982 microporous membrane Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- -1 4-ethyl-l-piperazinyl Chemical group 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000015114 espresso Nutrition 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940072132 quinolone antibacterials Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the invention relates to an antibacterial medicine for preventing and controlling aquatic diseases of livestock and poultry, in particular to an enrofloxacin injection and a preparation method thereof. Background technique
- Enrofloxacin (English name: Enrofloxacin), its chemical formula is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)- 3-quinolinecarboxylic acid (English name: 1, 4-dihydro-l-cyclopropyl-7- (4-ethyl-l-piperazinyl) -6 ⁇ f luoro-4-oxo-3-quinol i
- quinolone antibacterial drugs is a representative of a new generation of quinolone antibacterial drugs. It is a special new drug for the prevention and control of aquatic diseases in livestock and poultry. It not only retains the characteristics of broad-spectrum, high-efficiency, low toxicity, good absorption and convenient administration of quinolones, but also various Various infections caused by bacteria have significant effects, especially for various mycoplasma. The killing power of various mycoplasma is significantly higher than other drugs of quinolones and various drugs such as tylosin and tyrosin which have been used for many years. However, since enrofloxacin has a very strong bitter taste, when used as an oral dosage form, the tolerance of the animal is very low, so it is usually administered in the form of an injection in clinical use.
- Enrofloxacin is very soluble in water and dissolves in alkaline solvents, so the commonly used injection is an alkaline aqueous solution of enrofloxacin, the alkaline aqueous solution is an aqueous solution of sodium hydroxide, but enrofloxacin is in an alkaline aqueous solution.
- the solubility in the solution was 10%, and the excess portion precipitated in a crystalline form.
- the object of the present invention is to overcome the deficiencies of the prior art, and to provide an enrofloxacin injection having a neutral pH and no stimulation to an animal, wherein the content of enrofloxacin in the injection is 10 to 20%. It greatly increases the therapeutic effect of single administration, and the prepared enrofloxacin injection has stable traits and long-term storage without crystallization, which is a kind of injection with good therapeutic effect and no stimuli.
- the espresso agent is 0. 1 ⁇ 0. 5 parts.
- the chelating agent is 0. 1 ⁇ 0. 5 parts.
- the enrofloxacin accounts for 10 to 20% of the total weight of the solution.
- the antioxidant is sodium thiosulfate or sodium hydrogen sulfite.
- the chelating agent is EDTA.
- the invention also provides a preparation method of enrofloxacin injection, the method comprising the following steps:
- the sterilizing treatment is performed by using a 45.
- the concentration of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of the aqueous solution of The acidifying agent in the step (3) is one or two or three kinds of lactic acid, sodium butyrate or arginine.
- the antioxidant in step (4) is sodium thiosulfate or
- the enrofloxacin injection prepared by the present invention is added with one or two or three kinds of lactic acid, sodium butyrate or arginine, and finally the pH of the injection is made.
- Neutral which is not irritating when the animal is injected, and increases the amount of enrofloxacin in the injection to 20%, greatly increasing the therapeutic effect of a single administration, and simultaneously preparing the enrofloxacin injection. It has stable liquid properties and long-term storage without crystal precipitation. It is a kind of injection with good therapeutic effect and no stimulation.
- the present invention the singularity of the singularity of the singularity of the singularity of the singularity of the singularity of the singularity of the singularity of the singularity of the singularity. 5 ⁇
- the chelating agent 0. 1 ⁇ 0. 5 parts. Enrofloxacin accounts for 10 to 20% of the total weight of the solution.
- the antioxidant is sodium thiosulfate or sodium hydrogen sulfite.
- the chelating agent is EDTA (Ethyl ene Diamine Tetraacet i c Ac i d).
- a method for preparing enrofloxacin injection comprises the following steps:
- Step (5) After completion, the volume is adjusted to 100 ml with purified water, and the solution after constant volume is filtered through a microporous membrane of 0. 45 um;
- the enrofloxacin injection was tested to be neutral, and the enzyfloxacin content of the active ingredient in the solution injection was 20% of the total weight of the injection solution.
- a method for preparing enrofloxacin injection comprises the following steps:
- Step (5) After completion, the volume is adjusted to 100 ml with purified water, and the solution after constant volume is filtered through a microporous membrane of 0. 45 um;
- the enrofloxacin injection was tested to be neutral, and the enolfloxacin content of the active ingredient in the solution was
- a method for preparing enrofloxacin injection comprises the following steps:
- Step (5) After completion, the volume is adjusted to 100 ml with purified water, and the solution after constant volume is filtered through a microporous membrane of 0. 45 um;
- the enrofloxacin injection was tested to be neutral, and the enolfloxacin content of the active ingredient in the solution was
- a method for preparing enrofloxacin injection comprises the following steps:
- Step (5) After completion, the volume is adjusted to 100 ml with purified water, and the solution after constant volume is filtered through a microporous membrane of 0. 45 um;
- the enrofloxacin injection was tested to be neutral, and the enzyfloxacin content of the active ingredient in the solution was 18%.
- the enrofloxacin injection prepared by the present invention has stable composition and no precipitation during long-term storage.
- the enrofloxacin injection prepared by the present invention is not irritating to the animal, and the animal has no uncomfortable reaction after the administration.
- Table 3 Test results of therapeutic effect of chicken artificially infected Escherichia coli As can be seen from Table 3, the enrofloxacin injection prepared by the present invention has good curative effect and high cure rate.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020127021886A KR20130080422A (ko) | 2010-05-22 | 2011-05-20 | 엔로플록사신의 주사제 및 그의 제조방법 |
| AU2011257785A AU2011257785A1 (en) | 2010-05-22 | 2011-05-20 | Injection of enrofloxacin and producing method thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010179923.X | 2010-05-22 | ||
| CN201010179923XA CN101810569B (zh) | 2010-05-22 | 2010-05-22 | 一种恩诺沙星注射液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011147280A1 true WO2011147280A1 (zh) | 2011-12-01 |
Family
ID=42618033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2011/074426 WO2011147280A1 (zh) | 2010-05-22 | 2011-05-20 | 一种恩诺沙星注射液及其制备方法 |
Country Status (4)
| Country | Link |
|---|---|
| KR (1) | KR20130080422A (ko) |
| CN (1) | CN101810569B (ko) |
| AU (2) | AU2011101749A4 (ko) |
| WO (1) | WO2011147280A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810569B (zh) * | 2010-05-22 | 2011-09-21 | 鼎正动物药业（天津）有限公司 | 一种恩诺沙星注射液及其制备方法 |
| CN102772359A (zh) * | 2012-08-02 | 2012-11-14 | 挑战（天津）动物药业有限公司 | 一种恩诺沙星注射液及其制备方法 |
| CN104606671B (zh) * | 2014-12-30 | 2017-01-18 | 天津市中升挑战生物科技有限公司 | 一种复方溶菌酶恩诺沙星注射制剂 |
| CN104586757A (zh) * | 2015-01-08 | 2015-05-06 | 邳州正康生物技术有限公司 | 一种兽用恩诺沙星注射液及其制备方法 |
| CN107095848A (zh) * | 2017-07-01 | 2017-08-29 | 山东中牧兽药有限公司 | 一种恩诺沙星注射液及其制备方法 |
| CN112174888B (zh) * | 2019-07-04 | 2022-10-14 | 天津市中升挑战生物科技有限公司 | 一种恩诺沙星单晶型物及其制备方法 |
| CN111973553A (zh) * | 2020-09-03 | 2020-11-24 | 江西省科达动物药业有限公司 | 一种高稳定性的恩诺沙星注射液及其制备方法 |
| CN117530922B (zh) * | 2024-01-09 | 2024-04-26 | 中国农业大学 | 一种兽用高稳定性复方注射液及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177300A (zh) * | 1995-01-13 | 1998-03-25 | 拜尔公司 | 恩氟沙星注射液或输液 |
| CN101400351A (zh) * | 2006-03-08 | 2009-04-01 | 拜尔动物保健有限责任公司 | 含氟喹诺酮类化合物的药物制剂 |
| CN101810569A (zh) * | 2010-05-22 | 2010-08-25 | 鼎正动物药业（天津）有限公司 | 一种恩诺沙星注射液及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1288725A (zh) * | 2000-06-30 | 2001-03-28 | 程广亚 | 畜禽注射液及其系列产品的制备方法 |
| ES2315123B1 (es) * | 2006-09-25 | 2009-12-30 | Divasa-Farmavic, S.A. | Composiciones farmaceuticas estables de tetraciclinas en solucion, procedimiento para su obtencion y sus usos. |
| CN101301291B (zh) * | 2008-04-11 | 2010-09-01 | 天津生机集团股份有限公司 | 兽用复方恩诺沙星注射液及其制备方法 |
| CN101347432B (zh) * | 2008-09-05 | 2011-06-22 | 郑州后羿制药有限公司 | 一种畜禽用长效恩诺沙星注射液及其制备方法 |
-
2010
- 2010-05-22 CN CN201010179923XA patent/CN101810569B/zh not_active Expired - Fee Related
-
2011
- 2011-05-20 AU AU2011101749A patent/AU2011101749A4/en not_active Ceased
- 2011-05-20 AU AU2011257785A patent/AU2011257785A1/en active Pending
- 2011-05-20 KR KR1020127021886A patent/KR20130080422A/ko not_active Application Discontinuation
- 2011-05-20 WO PCT/CN2011/074426 patent/WO2011147280A1/zh active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177300A (zh) * | 1995-01-13 | 1998-03-25 | 拜尔公司 | 恩氟沙星注射液或输液 |
| CN101400351A (zh) * | 2006-03-08 | 2009-04-01 | 拜尔动物保健有限责任公司 | 含氟喹诺酮类化合物的药物制剂 |
| CN101810569A (zh) * | 2010-05-22 | 2010-08-25 | 鼎正动物药业（天津）有限公司 | 一种恩诺沙星注射液及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101810569B (zh) | 2011-09-21 |
| AU2011257785A1 (en) | 2012-08-30 |
| AU2011101749A4 (en) | 2015-02-05 |
| KR20130080422A (ko) | 2013-07-12 |
| CN101810569A (zh) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011147280A1 (zh) | 一种恩诺沙星注射液及其制备方法 | |
| RU2260429C9 (ru) | Составы моксифлоксацина, содержащие поваренную соль | |
| JPS6094910A (ja) | ピペラジニル―キノロンカルボン酸の乳酸塩の溶液 | |
| TW201431567A (zh) | 阿托莫西汀（ａｔｏｍｏｘｅｔｉｎｅ）溶液 | |
| CN106031710B (zh) | 一种富马酸氟呐普拉赞的注射剂及其制备方法 | |
| CN103126982A (zh) | 一种新兽药葡甲胺恩诺沙星注射液及其制备方法 | |
| CN104856946A (zh) | 一种高安全性的地塞米松磷酸钠注射液及其制备工艺 | |
| JP5535900B2 (ja) | ガチフロキサシン含有水性液剤、その製造方法、および、該水性液剤の低温保存および凍結融解時の沈殿生成を抑制する方法 | |
| JP6950966B2 (ja) | スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法 | |
| CN114796168A (zh) | 一种羧甲司坦雾化吸入用溶液制剂及其制备方法 | |
| CN103830240A (zh) | 一种氟喹诺酮药物组合物 | |
| CN110101875B (zh) | 一种钆塞酸二钠注射液药物组合物及其制备方法 | |
| CN102885766B (zh) | 一种右旋酮洛芬注射液及其制备方法 | |
| JP2018507224A (ja) | ウマにおける発熱の処置及び防止のための組成物及び方法 | |
| CN102068408A (zh) | 一种盐酸法舒地尔注射液及其制备方法 | |
| CN112569211A (zh) | 一种吸入用加替沙星溶液及其制备方法 | |
| CN105496954A (zh) | 一种肌松药物罗库溴铵的注射液的制备方法 | |
| CN110693822A (zh) | 一种布洛芬注射液及制备方法 | |
| CN105769756A (zh) | 一种富马酸西他沙星注射剂及其制备方法 | |
| JP6856813B1 (ja) | 亜鉛点滴静注用製剤 | |
| JP5217276B2 (ja) | 注射用抗菌剤の製造方法 | |
| CN107823130A (zh) | 一种汉防己碱注射制剂药物组合物的制备方法 | |
| RU2320352C2 (ru) | Способ лечения субклинического мастита у коров | |
| CN105663036A (zh) | 一种兽用氧氟沙星注射液及制备方法 | |
| CN103222954A (zh) | 一种含洛哌丁胺或其盐酸盐的溶液剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11786052 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011257785 Country of ref document: AU |
|
| ENP | Entry into the national phase |
Ref document number: 20127021886 Country of ref document: KR Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2011257785 Country of ref document: AU Date of ref document: 20110520 Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 29/01/2013) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11786052 Country of ref document: EP Kind code of ref document: A1 |